Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome-Reference-Cited by-同舟云学术

Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome

Published:2010-04 Issue:4 Volume:176 Page:1639-1647
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Harigopal Malini,Barlow William E.,Tedeschi Greg,Porter Peggy L.,Yeh I-Tien,Haskell Charles,Livingston Robert,Hortobagyi Gabriel N.,Sledge George,Shapiro Charles,Ingle James N.,Rimm David L.,Hayes Daniel F.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference50 articles.

1. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance;Allred;Arch Surg,1990

2. Prognostic and predictive factors in breast cancer by immunohistochemical analysis;Allred;Mod Pathol,1998

3. Progesterone receptors as a prognostic factor in stage II breast cancer;Clark;N Engl J Med,1983

4. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples;Goulding;Hum Pathol,1995

5. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples;Jonat;Cancer Res,1986

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine Learning for Digital Scoring of PRMT6 in Immunohistochemical Labeled Lung Cancer;Cancers;2023-09-15

2. Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores;JAMA Oncology;2023-09-01

3. Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores—Reply;JAMA Oncology;2023-09-01

4. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center;Modern Pathology;2023-07

5. The HER2-low revolution in breast oncology: steps forward and emerging challenges;Therapeutic Advances in Medical Oncology;2023-01